Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit? (original) (raw)
Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis
Giangiacomo Torri
Journal of Thrombosis and Haemostasis
View PDFchevron_right
Low-Molecular-Weight Heparins: Are they all the Same?
Jeffrey Ginsberg
British Journal of Haematology, 2003
View PDFchevron_right
Comparison of low-molecular weight heparins to unfractionated heparin
Robert Berent
European Heart Journal, 2001
View PDFchevron_right
Preclinical studies on a low molecular weight heparin
Ahmad ridhani ahsan
Thrombosis Research, 1996
View PDFchevron_right
Pharmacological and clinical evidence for the use of low-molecular-weight heparins in acute coronary syndromes
Guido Rosito
Arquivos Brasileiros de Cardiologia, 2001
View PDFchevron_right
The Anticoagulant and Nonanticoagulant Properties of Heparin
Gerry Nicolaes
Thrombosis and Haemostasis
View PDFchevron_right
Antithrombotic and bleeding effects of a low molecular weight heparin fraction
Giangiacomo Torri
Biochemical Pharmacology, 1985
View PDFchevron_right
Low-molecular-weight heparin for thromboprophylaxis
Giuseppe Camporese
Current opinion in pulmonary medicine, 2009
View PDFchevron_right
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin
Alberto Quispe
American Heart Journal, 2000
View PDFchevron_right
Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010
Jawed Fareed
Seminars in Thrombosis and Hemostasis, 2008
View PDFchevron_right
Low-molecular weight heparins in coronary artery disease
Dan Hunt
Current Atherosclerosis Reports, 2001
View PDFchevron_right
Homogeneous low-molecular-weight heparins with reversible anticoagulant activity
truong pham
Nature Chemical Biology, 2014
View PDFchevron_right
Old and new applications of non-anticoagulant heparin
giuseppe cassinelli
International journal of cardiology, 2016
View PDFchevron_right
Low-Molecular-Weight Heparins for the Prevention and Treatment of Venous Thromboembolism
Gia Dice
Military Medicine, 2001
View PDFchevron_right
Evaluation of the in vitro and in vivo therapeutic equivalence of two pharmaceutically equivalent heparin products
Yasser Bustanji
2011
View PDFchevron_right
Heparins: Clinical use and laboratory monitoring
Julia Davis
Laboratory Medicine, 2010
View PDFchevron_right
Low-molecular-weight heparin (LMWH) in the treatment of thrombosis
René G Holzheimer
European journal of medical research, 2004
View PDFchevron_right
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
Jose Nicolau
Journal of Thrombosis and Thrombolysis, 2012
View PDFchevron_right
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
Jerome Premmereur
The New England Journal of Medicine, 1997
View PDFchevron_right
Unfractionated heparin as a safe alternative in a case of low molecular weight heparin-induced thrombocytosis: A case report
Moustafa Elshafei
Annals of Medicine and Surgery, 2021
View PDFchevron_right
Low-molecular-weight heparins in acute myocardial infarction: RationaLe and results of a pilot study
Karin Coyne
Clinical Cardiology, 2000
View PDFchevron_right
Combinations of Low Doses of Unfractionated Heparin and of Low-Molecular-Weight Heparin Prevent Experimental Venous Thrombosis
Francisco Humberto De Abreu Maffei
Pathophysiology of Haemostasis and Thrombosis, 2005
View PDFchevron_right
Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention
Graham Wong
JAMA, 2003
View PDFchevron_right
Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
Prof. Fahad A S Aleidan
Mediterranean Journal of Hematology and Infectious Diseases, 2015
View PDFchevron_right
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
James Dalen
Chest, 1992
View PDFchevron_right
Why Is Heparin, Despite Being an Anticoagulant, Rarely Associated with Blood Clotting? A Systematic Review
Liberty Omorogbe
2021
View PDFchevron_right
Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism
menab men
View PDFchevron_right
Emergence of Low-Molecular-Weight Heparins in Cardiology
Kathleen Stringer
Pharmacotherapy, 1999
View PDFchevron_right
The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products
Andrew Nicolaides
Clinical and Applied Thrombosis/Hemostasis, 2008
View PDFchevron_right
Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia
B. Chong
Thrombosis Research, 1996
View PDFchevron_right
Heparin, Low Molecular Weight Heparin, and Derivatives in Thrombosis, Angiogenesis, and Inflammation: Emerging Links
Shaker Mousa
Seminars in Thrombosis and Hemostasis, 2007
View PDFchevron_right
Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial
Jerome Premmereur
The American Journal of Cardiology, 1998
View PDFchevron_right
2 Mechanisms of action of low molecular weight heparins and heparinoids
Fred A Ofosu
Baillière's Clinical Haematology, 1990
View PDFchevron_right
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
Jack Hirsh
The Journal of Urology, 1998
View PDFchevron_right
Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin
Peter Nilsson-Ehle
European Journal of Clinical Investigation, 1985
View PDFchevron_right